SurModics Inc (SRDX)

[Democritus_of_Abdera]

Aslan... The triamcinolone toxicity study by Yu et al (Retina 26:531, 2006) that you pointed me to is indeed relevant regarding the use SRDX’s I-vation platform.

I find it important that when the 0.1 ml solution was injected intravitreally, it gathered into a pool between the vitreous and retina at the gravitational bottom of the eye. The size of the pool diminished over the two week study, but was still evident on day 14..... It leads me to wonder if intravitreal injections of other drugs pool as a reservoir at a localized site between the retina and vitreous rather than distributing throughout the vitreous as I have thought. Such pooling could lead to localized toxicity such as these authors showed... a toxicity problem that could be circumvented with an implant placed specifically at a location chosen by the ophthalmologist.

Actually, I was surprised that such a large injection volume was employed... Do you know what injection volumes are normally used by ophthalmologists treating retinal disorders?